Press Releases

and/or
572 News Releases found
Pictured: Mark Kris
New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for the disease.
Pictured: William Tap
New research from Memorial Sloan Kettering highlighted in advance of the 50th Annual Meeting of the American Society of Clinical Oncology demonstrates the powerful clinical benefit of giving patients a drug that targets the molecular abnormality driving the growth of advanced pigmented villonodular synovitis, a rare and debilitating joint disease.
Three winners of the first-ever Breakthrough Prizes — Charles L. Sawyers, MD, of Memorial Sloan Kettering Cancer Center; Cornelia I. Bargmann, PhD, of the Rockefeller University; and Lewis C. Cantley, PhD, of Weill Cornell Medical College — have committed a portion of their Breakthrough Prize in Life Sciences award to establish a new annual prize for promising postdoctoral trainees.
Memorial Sloan Kettering has launched a collaborative translational research center that will unite researchers specializing in two rapidly growing fields: molecular imaging and nanotechnology.
cancer cell
New research from Memorial Sloan Kettering provides fresh insight into the biologic mechanisms that individual cancer cells use to metastasize to the brain.
Memorial Sloan Kettering announced the appointment of Pereira & O’Dell in New York as its creative agency of record and Media Storm as its media agency of record.
Pictured: Renier Brentjens, Isabelle Rivière, and Michel Sadelain
The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells.
Media Advisory
A collaborative effort among cancer experts from Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College has yielded an interesting association: Obesity prior to diagnosis is associated with a five-fold increase in the risk of death from early-stage squamous cell carcinoma of the tongue.
David Scheinberg
Memorial Sloan Kettering and Eureka Therapeutics recently entered into a licensing agreement with Novartis to develop a unique monoclonal antibody.
Pictured: Jedd Wolchok and Alexander Rudensky
Media Advisory
Memorial Sloan Kettering Cancer Center, along with five other elite academic institutions, will share an unprecedented total of $540 million in new financial support from Ludwig Cancer Research.